Stromal Tumours News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Glenmark launches affordable drug to treat kidney cancer in India
Glenmark launches affordable drug to treat kidney cancer in India
16 February 2021 | News
The drug is launched at a MRP that is approximately 96 per cent lower than the MRP compared to the innovator brand, priced at Rs 7000 (50 mg), Rs 3600 (25 mg) and Rs 1840 (12.5 mg) per month
Source credit: Shutterstock
Glenmark Pharmaceuticals has launched SUTIB, the generic version of Sunitinib oral capsules to treat kidney cancer in India. The drug is launched at a MRP that is approximately 96 per cent lower than the MRP compared to the innovator brand, priced at Rs 7000 (50 mg), Rs 3600 (25 mg) and Rs 1840 (12.5 mg) per month. Sunitinib is also approved by the US Food and Drug Administration (US FDA).  ....

Alok Malik , Group Vice , Drug Administration , Glenmark Pharmaceuticals , Group Vice President , Business Head , India Formulations , Kidney Cancer , Stromal Tumours , Advanced Renal Cell Carcinoma , Pancreatic Neuroendocrine Tumours , அலோக் மாலிக் , குழு துணை , க்ளேண்மர்க் மருந்துகள் , குழு துணை ப்ரெஸிடெஂட் , வணிக தலை , இந்தியா சூத்திரங்கள் , கிட்நீ புற்றுநோய் ,